SCHEMBL26074552

SCHEMBL26074552

COCc1ccc(-c2ccc(-c3cc(C(=O)O)c4cc(I)ccc4n3)nc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EIF4A1 P60842 5/20 0.50
▸ DHODH Q02127 7/20 0.42
▸ KDM4E B2RXH2 3/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ HPGD P15428 2/20 0.42
▸ PTGES O14684 1/20 0.42
▸ ALOX5 P09917 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CASP7 P55210 1/20 0.42
▸ HIF1A Q16665 1/20 0.42
▸ EPRS1 P07814 1/20 0.41
▸ KCNH2 Q12809 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26074561 0.90 EIF4A1 (0.45) EIF4A1DHODHKDM4EHSD17B10SMN1; SMN2
SCHEMBL25118630 0.89 DHODH (0.57) EIF4A1DHODHKDM4EHSD17B10SMN1; SMN2
SCHEMBL26075654 0.89 KDM4E (0.53) EIF4A1DHODHKDM4EHSD17B10SMN1; SMN2
SCHEMBL26074473 0.87 KDM4E (0.56) EIF4A1DHODHKDM4EHSD17B10SMN1; SMN2
SCHEMBL26074608 0.86 DHODH (0.51) EIF4A1DHODHKDM4EHSD17B10SMN1; SMN2
SCHEMBL25118616 0.85 DHODH (0.46) EIF4A1DHODHKDM4EHSD17B10SMN1; SMN2
SCHEMBL26074571 0.85 DHODH (0.44) EIF4A1DHODHKDM4EHSD17B10SMN1; SMN2
SCHEMBL26074463 0.84 KDM4E (0.58) EIF4A1DHODHKDM4EHSD17B10SMN1; SMN2
SCHEMBL26074576 0.82 EIF4A1 (0.46) EIF4A1DHODHKDM4EHSD17B10MEN1
SCHEMBL26074580 0.82 EIF4A1 (0.46) EIF4A1DHODHKDM4EHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD EIF4A1 4791/4885DHODH 1/4885KDM4E 1396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback